Cellanyx

Cellanyx is a diagnostic company that has developed a first-in-class live-cell phenotypic platform for precision oncology. The company's technology utilizes microfluidics and machine learning to analyze living tumor cells directly from patient biopsies, providing a more accurate assessment of cancer aggression than traditional pathology. Their lead product focuses on prostate cancer, helping clinicians and patients decide between active surveillance and surgical intervention by predicting the risk of adverse pathology. By measuring dynamic cellular behaviors in a proprietary microenvironment, Cellanyx aims to reduce over-treatment and improve clinical decision-making across multiple solid tumor types.